Bio-Rad Laboratories has announced new Bio-Plex Pro human diabetes assay panels for its Bio-Plex suspension array system
Offered as one multiplex and two singleplex assays designed to achieve optimal working assay ranges, the new pro-human diabetes assay delivers accurate and reproducible multiplex measurements of human diabetes and obesity markers.
The Pro-human assay panel consists of a premixed 12-plex of analytes (C-Peptide, ghrelin, GIP, and visfatin);GLP-1, glucagon, IL6, insulin, leptin, PAi-1, resistin, TNF- work with magnetic beads, pre-blended detection antibodies, standards and controls.
The singleplex assays (adiponectin and adipsin) may be mixed together to form a two-plex assay.
The reagent kit includes an assay buffer, wash buffer, streptavidin-PE, 96-well filter plate, sealing tape, and panel specific instructions required to prepare assays and acquire data.
The diluents kit enables the researcher to choose the appropriate diluents kit for diluting samples, standards and controls.
All three Bio-Plex pro-human diabetes assays were validated using real patient samples.
The three main types of human diabetes are Type 1, Type 2, and gestational.
While Type 1 diabetes is known to have a genetic basis, the underlying causes of Type 2 and gestational diabetes include both genetic and environmental (behavioural) factors.
The genetic and environmental factors and the interaction between them are broad areas of research.
Based on CDC's national Health Interview Survey statistics, approximately 7% of the population in the USA has diabetes and of these approximately 30% are undiagnosed.
In the USA, approximately 1.5 million people are diagnosed with diabetes each year, with annual economic costs estimated at approximately $98 billion.
The obesity epidemic is a main contributor to the projected rise in these numbers.
According to the World Health Organization, over 50% of the population of the USA, Europe, and Australia, as well as low to moderate income countries such as India, Russia, Mexico and Egypt are overweight or obese and thus at risk for developing diabetes.
Over 83% of diagnosed cases of diabetes are Type 2.
Overall, 75% of those suffering from diabetes will succumb to heart disease or stroke.
Approximately $92 billion is spent annually in the USA on direct medical costs resulting from diabetes.
